BioCryst Pharmaceuticals, Inc. (BCRX)
8.17
+0.05
(+0.62%)
USD |
NASDAQ |
Oct 02, 16:00
8.15
-0.02
(-0.24%)
After-Hours: 20:00
BioCryst Pharmaceuticals Net Income (Quarterly) : 78.40M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 78.40M |
| March 31, 2026 | -721.81M |
| December 31, 2025 | 245.84M |
| September 30, 2025 | 12.90M |
| June 30, 2025 | 5.085M |
| March 31, 2025 | 0.032M |
| December 31, 2024 | -26.80M |
| September 30, 2024 | -14.03M |
| June 30, 2024 | -12.67M |
| March 31, 2024 | -35.38M |
| December 31, 2023 | -61.73M |
| September 30, 2023 | -36.15M |
| June 30, 2023 | -75.33M |
| March 31, 2023 | -53.33M |
| December 31, 2022 | -71.54M |
| September 30, 2022 | -42.52M |
| June 30, 2022 | -58.86M |
| March 31, 2022 | -74.20M |
| December 31, 2021 | -17.78M |
| September 30, 2021 | -58.80M |
| June 30, 2021 | -43.20M |
| March 31, 2021 | -64.28M |
| December 31, 2020 | -60.49M |
| September 30, 2020 | -46.12M |
| June 30, 2020 | -38.61M |
| Date | Value |
|---|---|
| March 31, 2020 | -37.60M |
| December 31, 2019 | -2.622M |
| September 30, 2019 | -37.59M |
| June 30, 2019 | -37.63M |
| March 31, 2019 | -31.05M |
| December 31, 2018 | -27.43M |
| September 30, 2018 | -29.60M |
| June 30, 2018 | -18.45M |
| March 31, 2018 | -25.78M |
| December 31, 2017 | -19.54M |
| September 30, 2017 | -15.13M |
| June 30, 2017 | -16.89M |
| March 31, 2017 | -14.22M |
| December 31, 2016 | -4.503M |
| September 30, 2016 | -11.53M |
| June 30, 2016 | -16.28M |
| March 31, 2016 | -22.83M |
| December 31, 2015 | -18.14M |
| September 30, 2015 | -14.62M |
| June 30, 2015 | 4.901M |
| March 31, 2015 | -15.16M |
| December 31, 2014 | -11.67M |
| September 30, 2014 | -8.731M |
| June 30, 2014 | -14.65M |
| March 31, 2014 | -10.14M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Amgen, Inc. | 2.375B |
| Halozyme Therapeutics, Inc. | 229.91M |
| Neurocrine Biosciences, Inc. | 144.40M |
| Vertex Pharmaceuticals, Inc. | 1.100B |
| Agenus, Inc. | -0.567M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 218.25M |
| Total Expenses (Quarterly) | 139.86M |
| EPS Diluted (Quarterly) | 0.2957 |
| Enterprise Value | 2.569B |
| Gross Profit Margin (Quarterly) | 98.01% |
| Profit Margin (Quarterly) | 35.92% |
| Earnings Yield | -18.41% |
| Operating Earnings Yield | 19.89% |
| Normalized Earnings Yield | 6.835 |